• Pioneering GPS-enabled location device developer MetAlert is building on two decades of experience with new products designed to broaden its suite of technology for remote patient monitoring (“RPM”) in an unobtrusive manner plus monitoring seniors for falls
• MetAlert recently announced that it has engaged the financial strategy advisory firm Joseph Gunnar & Co., LLC to help direct its decisions ranging from acquisitions to potential up listing on a national exchange
• The company’s products include its flagship patented shoe insole device enabled with GPS, Bluetooth, and Wi-Fi functionality for tracking seniors or people with autism prone to wandering and getting lost, as well as protecting potential kidnapping targets
• MetAlert’s latest product developments provide artificial intelligence as an accessory to identify fall risks and provide related analysis of patients’ physical functioning, while allowing the patient to maintain a degree of privacy and independence

Medical patient location device developer MetAlert (OTC: MLRT) is launching a suite of wearable companion products to its innovative SmartSole shoe insole units and, on the heels of rebranding the company to better represent its strategic direction, recently announced that it has engaged financial advisory firm Joseph Gunnar & Co., LLC to guide its financing and acquisition decisions.

“MetAlert is approaching the inflection point of its growth curve by its ability to sell a multitude of products and services to a broader audience, which will result in greater revenue per user (“RPU”),” MetAlert CEO Patrick Bertagna stated (https://ibn.fm/0eYGw). “We are thrilled to align with a proven advisor like Joseph Gunnar in our quest to maximize shareholder value.”

The patented GPS-enabled SmartSole is a non-intrusive tracking device designed to monitor the location of people with cognitive memory disorders such as Alzheimer’s Disease who tend to get lost or wander. The tech-designed insole may also be used by people at risk of kidnapping, such as children, government employees and select professionals.

A next-generation shoe insole branded SmartSole plus incorporates biometric sensors paired with smart analytics to analyze the wearer’s movements for assessing overall health and wellness, and the company’s most recent product rollout — the in-home RoomMate system — uses 3D infrared motion-sensitive technology to allow caregivers to remotely monitor fall-prone loved ones in an unobtrusive manner.

Such developments have given the location technology pioneer a new progressive profile designed to encourage investors and strengthen the company’s profitability (https://ibn.fm/eTt7E).

The market potential for location and fall-monitoring devices is demonstrated by Centers for Disease Control and Prevention reporting that notes U.S. emergency departments treat 3 million older adults each year for fall injuries and more than 650,000 people are believed to have died each year as a result of accidental falls (https://ibn.fm/IGNcY).

MetAlert’s international distribution supply chain serves customers in over 40 countries as well as U.S. clients ranging from police departments to assisted living facilities.

Developments anticipated during the first months of 2023 include the rollout of Bluetooth-enabled devices that will collect patients’ health data such as their vitals and, in connection with the GPS SmartSole plus HUB and artificial intelligence software, will analyze trends and provide responsiveness according to preset alert parameters.

A small GPS tracker shorter than the length of a credit card will provide the same functionality as the insoles and have a two-week battery life between charging.

For more information, visit the company’s website at www.MetAlert.com.

NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT

• Correlate addresses anticipated questions about energy retrofits for the commercial and industrial sector through its industry-leading advanced energy solution and financing platform
• The company is reducing the overall barrier of entry into the renewable energy space while also aiding in the installation and overall maintenance of high-efficiency infrastructure
• The company has developed a network of financing partners to cater to project needs, allowing even more customers to access renewable energy solutions for their buildings to reduce their overall carbon footprint, while helping to ensure positive economic return of retrofits in a much shorter timeframe

According to the National Renewable Energy Laboratory, buildings are the largest consumers of energy and one of the largest sources of greenhouse gas (“GHG”) emissions in the United States. They account for 70% of electricity use and about 40% of total primary energy consumption in the country. In 2020, carbon dioxide (“CO2”) from energy use in buildings accounted for about 37% of global emissions (https://ibn.fm/9TgmT). To remedy the situation, electrification retrofits that remove fossil gas are being seen as a critical climate solution, given their overall efficiency and sustainability. Legitimate concerns that building owners have regarding short and long-term returns of potential retrofits are addressed by Correlate Infrastructure Partners (OTCQB: CIPI), a distributed energy solutions company, through its advanced energy solution and financing platform. Correlate, providing efficient and affordable energy solutions across North America, sees the scaling of distributed clean energy solutions as critical and doable in countering the effects of climate change. Through its two subsidiaries, Correlate and Solar Site Design, the company sees a unique market opportunity to reduce site-specific energy consumption and deploy clean energy generation and clean energy solutions at scale, focusing on retrofitting commercial buildings. Through its unique commercial and industrial sector platform, Correlate meets the economic concerns of building owners in retrofitting their establishments. The company is reducing the overall barrier of entry into the renewable energy space with its finance model while also aiding in the installation and overall maintenance of the installed infrastructure, ultimately making it easier for customers to transition to renewable energy alternatives. Since its inception, Correlate has sought to remove friction between today’s legacy finance processes and the needed clean-energy upgrades developed within its program technologies. To this end, it has developed a network of financing partners to cater to most project financing needs. This allows even more customers access to renewable energy solutions for their buildings and proper energy management and improvement projects specifically tailored to reduce the overall buildings’ carbon footprint. As the cost of solar components continues to drop, Correlate is confident that more building owners will embrace solar power as an alternative energy source to lower their carbon footprint. The company’s management is also confident that through its finance platform and the network built so far, Correlate will continue to offer value to its customers, guaranteeing the economic return of their retrofits in a much shorter timeframe. “Correlate Infrastructure Partners is making energy management and procurement transparent and cost-effective as we digitize the process that has been archaic for way too long,” noted Todd Michaels, Correlate’s CEO. “We are excited to be at the forefront of an industry that is at an inflection point, and we are eager to begin working to change the way commercial real estate owners optimize energy assets,” he added (https://ibn.fm/qnu3Q). For company information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.correlateinfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.correlateinfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• Meta was recently fined $275 million by the Irish Data Protection Commission stemming from a hack in 2019, which led to the leak of over 533 million users’ personal data
• By 2023, over 65% of the world’s population is set to be subject to data protection laws, up from only 10% in 2020
• This number is set to gain further impetus with the recent passing of the U.S. ADPPA law, which will afford U.S. internet users similar rights to those granted under the European Union’s GDPR laws
• Reklaim Ltd. has looked to assist companies in incorporating the demands of a rapidly evolving privacy landscape into their data strategies

In the weeks leading up to August 2019, matters were tense at Meta (previously Facebook). A security hack had exposed personal information on over 533 million Facebook users spread across 106 countries. The social media company subsequently revealed that it had discovered and fixed the issue in August 2019, expressing confidence that the same route could no longer be used to scrape data. Less than 24 months later, phone numbers, full names, locations, and email addresses drawn from the hacked user profiles were posted to an amateur hacking forum (https://ibn.fm/vOKpp). The matter has now come to a head, with Ireland’s Data Protection Commission fining Facebook parent Meta roughly $275 million – taking the cumulative fines the regulator imposed on Meta since last year to over $900 million. With data privacy regulations turning increasingly stringent, companies and users alike have placed greater emphasis on safeguarding their online data – a phenomenon that Reklaim (TSX.V: MYID) (OTCQB: MYIDF) has sought to address. By 2023, 65% of the world’s population is set to have its personal data covered under modern privacy regulations, up from a mere 10% in 2020 (https://ibn.fm/Gbm5K). “With more countries introducing modern privacy laws in the same vein as the General Data Protection Regulation (‘GDPR’), the world has reached a threshold where the European baseline for handling personal information is now the de facto global standard,” Nader Henein, research vice president at Gartner, said in a news release. The strong momentum underpinning the expansion of global data privacy laws has made it imperative for businesses to incorporate the demands of a rapidly evolving privacy landscape into their data strategies. A failure from a business’s security and risk management department to adapt their personal data handling practices could increasingly expose the company to loss through fines or reputational damages, as highlighted by Meta’s recent travails. The ongoing evolution of consumer data and privacy rules has largely influenced Reklaim Ltd.’s business model. The company’s revolutionary systems allow consumers to log in to its platform and confirm their identity, unlocking data collected on them that has been bought and sold for years without their explicit consent. At that point, consumers can take control of their data and, if they choose, receive compensation for its use. With consent secured, Reklaim offers the data to Fortune 500 brands, platforms, and data firms. The company also has a subscription service for consumers that shrinks the amount of data leaking from their devices and delivers alerts on password and third-party data breaches (https://ibn.fm/0O5Hs). Reklaim’s data provision services have gained additional relevance amidst a spate of new consumer privacy regulations coming into effect. The recently passed federal American Data Privacy and Protection Act (“ADPPA”), a new privacy law promising Americans many of the same consumer privacy rights as the European Union’s General Data Protection Regulation (“GDPR”), will make the protection of online consumer data privacy a nationwide requirement. Meanwhile, on a state level, the California Consumer Privacy Act (“CCPA”) will become fully operational as of January 1, 2023, with the regulations affording consumers the right to know about the personal information a business collects about them as well as how it is used and shared (https://ibn.fm/L64ru). With the data privacy market in the U.S. and globally set to grow at a breakneck pace in the coming years, Reklaim Ltd. looks well positioned to capitalize. For more information, visit the company’s website at www.ReklaimYours.com. NOTE TO INVESTORS: The latest news and updates relating to MYIDF are available in the company’s newsroom at https://ibn.fm/MYIDF

• CNS Pharmaceuticals is a biopharmaceutical company that focuses on developing novel treatments for primary and metastatic cancers in the brain and central nervous system
• The company is currently evaluating the efficacy of Berubicin, a novel anthracycline that appears to cross the blood-brain barrier, in a potentially pivotal Phase 2 trial involving patients with recurrent glioblastoma multiforme (“GBM”)
• CEO John Climaco recently participated in the Virtual Investor “Ask the CEO” Event in which he provided an update on recent key events and plans for the future in addition to allaying the investors’ concerns regarding the recent reverse stock split
• CNS Pharmaceuticals also announced the pricing of a public offering that closed December 5; the company intends to use the net proceeds of the offering for its ongoing trial, R&D, and working capital

CNS Pharmaceuticals (NASDAQ: CNSP) CEO John Climaco recently participated in the Virtual Investor “Ask the CEO” Event held December 6. As part of the virtual event, Climaco discussed his and the company’s background, provided an update on recent key events and plans for the 2023 calendar year, and assuaged investors’ concerns regarding the recent reverse stock split. Lastly, Climaco also fielded questions from the investment community (https://ibn.fm/bEl2S). A clinical-stage biopharmaceutical company focused on developing novel treatments for primary and metastatic cancers in the brain and central nervous system, CNS Pharmaceuticals is presently enrolling patients in a potentially pivotal Phase 2 trial to evaluate the efficacy of Berubicin, its flagship drug candidate for the treatment of glioblastoma multiforme (“GBM”) and potentially other forms of cancer. So far, according to Climaco, the enrollment is approaching 70 patients against a target of 243 patients, a remarkable achievement since it began about 14 months earlier. “Patients are a lifeblood of a trial like this,” Climaco explained. “Our target is recurring and refractory GBM patients, and sadly in this deadly cancer, almost everyone will recur. And when they do, they do not have any approved treatment option anywhere in the world…. We’ve now offered those patients a chance at a chemotherapy that we believe can have efficacy and change the outcome of this disease.” GBM is an aggressive brain tumor with an average overall survival rate of only 10-12 months. “Most patients experience recurrence or progression of their disease within 12 months after frontline therapy and face a dismal outcome with no effective therapy,” a 2019 study explains (https://ibn.fm/q6snr). This lack of effective therapy is partly because conventional anthracyclines cannot cross the blood-brain barrier. But Berubicin changes this narrative as it is the first anthracycline with the demonstrated ability to cross this barrier and kill brain tumor cells otherwise unreachable by other therapies. “In other words,” the company’s website underlines, “Berubicin may become an effective treatment against glioblastoma, the most aggressive type of brain cancer.” To prove this hypothesis and demonstrate the drug candidate’s efficacy, CNS Pharmaceuticals set out to undertake an elaborate potentially pivotal Phase 2 trial designed in close collaboration with the US Food and Drug Administration (“FDA”). The trial aims to establish whether Berubicin extends overall survival, the primary endpoint of the trial and, as Climaco explained, “the only endpoint the FDA recognizes as the approvable endpoint.” The trial’s design encompasses a built-in interim analysis that will commence when the company enrolls 30-50% of the targeted figure and will last for six months. “When that [six-month period elapses], we will examine that data, and we will look to see if those patients are living longer than they are in the control arm. And if they are, and we believe they will, the study will continue. Our firmest hope is the data will be so conclusive that we may have the opportunity to discuss an accelerated approval with the FDA,” Climaco continued. CNS Pharmaceuticals expects to release the data from this interim analysis, potentially in mid-2023. The company believes that Berubicin, an anthracycline, has a real shot at changing the game in GBM in a way no one else has been able to do before. At the same time, the company believes Berubicin could be used to treat multiple other cancers, with Climaco describing the drug candidate as a “sledgehammer in oncologists’ toolkit.” Moreover, Climaco explained the reasons behind the company’s move to undertake a 1-for-30 reverse split of its common stock, which was announced November 28 (https://ibn.fm/wTksP). The split freed up shares, allowing the company to announce a $6 million public offering that closed December 5 (https://ibn.fm/2Ikp9). As part of this latest capital raise, CNS announced the pricing of a public offering of an aggregate of 1,889,764 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 1,889,764 shares of common stock at a combined offering price of $3.175 per share. The warrants were immediately exercisable at an exercise price of $3.03 per share and will expire five years after the initial exercise date. In addition, CNS also announced amendments to certain existing warrants. CNS Pharmaceuticals intends to use the net proceeds of the offering for its Phase 2 clinical trial, other research and development initiatives, and working capital. Following this most recent capital raise, the company is fully funded until late Q3 into early Q4 2023. A recording of the Virtual Investor “Ask the CEO” Event is available for 90 days post-event via https://ibn.fm/7aFjv. For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• REZYFi is targeting licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners who seek a variety of real estate-related first and additional mortgage-based financing and project-specific financing
• The sale of legal recreational marijuana in California in 2016 reached $2.69 billion and is expected to grow to $6.59 billion by 2025. Since passing laws for recreational marijuana, California saw a 50% increase in the legal marijuana market from 2017 to 2018
• REZYFi is licensed in 36 states and plans to expand to all states in the future

Throughout most of 2022, mortgage rates were rising due to the Federal Reserve’s increased interest rates to counter soaring inflation. However, mortgage rates have started dropping in recent weeks, reporting a downward trend for the fifth consecutive week. According to Freddie Mac, the 30-year fixed-rate mortgage averaged 6.31% in the week ending December 15, down from 6.33% during the week prior. According to the Mortgage Bankers Association, there has been an uptick in mortgage applications, with more people looking to take advantage of the trend in lower rates (https://ibn.fm/CXJOi). REZYFi is a real estate-oriented mortgage company servicing the needs of both traditional and non-traditional consumers and businesses. The company’s target markets include licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners who seek a variety of real estate-related first and additional mortgage-based financing and project-specific financing, like solar installations or real estate development projects. REZYFi has positioned itself as one of the first cannabis mortgage bankers in the United States – an area that traditional bankers are still reticent to serve. Through its two wholly owned subsidiaries – REZYFi Lending and ResMac Inc. – REZYFi is addressing an emerging real estate market with its financing opportunities, traditional mortgage, origination, correspondent, and servicing operations. The company leverages a wide network to offer options such as 15- and 30-year fixed-rate loans, FHA loans, VA loans, reverse mortgages, jumbo loans, and adjustable-rate mortgages. REZYFi expects increased funding for marketing and loan agents, which will drive significant origination growth over the next two years, supported by the planned launch of a high-margin cannabis division later this year. ResMac has been in operation for 13 years and has closed more than 20,000 loans for more than 15,000 clients. The company expects to accumulate $285 million in retail origination in 2023, alongside $250 million in wholesale origination for the same period. ResMac is further targeting $600 million in origination through its mortgage correspondent operations for 2023. In 2016, the sale of legal recreational marijuana in California – the world’s largest cannabis market – was valued at $2.69 billion and is expected to grow to $6.59 billion by 2025. Since passing laws for recreational marijuana in 2016, California saw a 50% increase in the legal marijuana market from 2017 to 2018 (https://ibn.fm/H74Qg). Using its corporate strengths – experience, a network of independent brokers, and proprietary technology – REZYFi offers a diversified approach to the real estate lending sector, which positions it to capitalize on growth in multiple verticals in the years to come. Licensed in 36 states, the company plans to expand to all states in the future. For more information, visit the company’s website at www.REZYFi.com. NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://ibn.fm/REZY

• SMBs are increasingly vulnerable to cyberattacks, from attacks on internal customer and employee records to proprietary secrets, and, although there are no foolproof solutions, there are now affordable and proven ways for SMBs to significantly mitigate the risks
• SideChannel’s team of vCISOs (virtual-based Chief Information Security Officer) possess a combined 400-plus years of experience in cybersecurity, offering creative solutions in the form of a bespoke cybersecurity program perfectly sized for growing enterprises
• The global cybersecurity market was valued at $139.77 billion in 2021 and is expected to reach $155.83 billion in 2022

The rapid digitization of supply chains creates serious new security risks. According to predictions by Gartner, 45% of organizations worldwide will have experienced cyberattacks on their software supply chains by 2025. With 60% of the current workforce working remotely, organizations are more vulnerable to attacks. They recommend that security leaders look beyond traditional approaches to security monitoring, detection, and response, to manage wider risks (https://ibn.fm/JnH6G). SideChannel (OTCQB: SDCH) is simplifying cybersecurity for mid-market companies by matching them with highly experienced information security officers at a cost lower than building an in-house information security team or hiring a full-time Chief Information Security Officer (“CISO”). Comprised of a team of virtual CISOs (“vCISOs”), SideChannel possesses a combined 400-plus years of experience in cybersecurity, lending its talent to clients and creating value in the form of cybersecurity programs perfectly sized for growing enterprises. Small- to mid-sized businesses (“SMBs”) are especially vulnerable to breaches and cyberattacks. The fast-growing cannabis industry has also seen a rise in cyberattacks, from breaches in information security at the point-of-sale terminals to internal customer and employee records to cultivators who risk losing proprietary formulas or having a crop ruined by ransomware attacks, making it imperative for solutions to be implemented to mitigate cyberattack risks. It isn’t just the cannabis industry; retail establishments, farming initiatives, and other businesses (of all sizes) are vulnerable to attacks. Implementing a zero-trust philosophy is one way to safeguard against cloud-based cybercrime (https://ibn.fm/p5jdw). The main principle behind zero trust is to authenticate everything – trusting no one without authorization or authentication. This security measure is critical to protect businesses from threats when shielding data and the infrastructure stored in the cloud. With data privacy laws becoming increasingly strict, 2023 will be no different – with the laws becoming more stringent. Over the next year, several new laws are expected to go into effect. Many data privacy laws require businesses to change how they store and process data; however, new implementation can pose a risk if not done correctly. As a result, the global cybersecurity market is also expanding. The market was valued at $139.77 billion in 2021 and is expected to reach $155.83 billion in 2022. Growing at a CAGR of 13.4% during the forecast period, the market is expected to reach $376.32 billion by 2029. The driving factors for the market’s growth are the emergence of online e-commerce platforms, the advent of core technologies like the internet of things (“IoT”), artificial intelligence (“AI”), and the implementation of remote workforce settings (https://ibn.fm/eaUM9). SideChannel is committed to creating top-tier cybersecurity programs for SMBs to help protect their data and assets. To date, the company has created more than 50 multi-layered cybersecurity programs for its clients. They have honed their skills and abilities in places like Anthem, Dick’s Sporting Goods, Best Buy, TD Bank, and the Pentagon. SideChannel continues to expand its service offerings, workforce, and customer base, attracting over 20 vCISOs to serve across industries, including fintech, biotech, healthcare, manufacturing, legal, defense, and technology services. For more information, visit the company’s website at www.SideChannel.com. NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH

• Luis Merchan was appointed President of Consumer Goods at Flora in July 2020 before being appointed as the company’s CEO five months later, and chairman of its Board of Directors in May 2022
• Merchan would lend his years of experience at Macy’s, where he led various sales and marketing initiatives, including the B2B corporate team responsible for bringing in $160 million in annual revenue
• Under his leadership, Flora has transitioned from the development stage to a full-scale international distributor with operations in over 12 countries worldwide. Mr. Merchan has also spearheaded several M&As, all of which have since set the company up for rapid growth
• Flora maintains its revenue guidance for FY 2022 to be between $35 and $45 million, incorporating revenue contributions from its various operating divisions, including Vessel Brand

In July 2020, Flora Growth (NASDAQ: FLGC), a cannabis cultivator, brand manufacturer, and global distributor, appointed Luis Merchan as the President of Consumer Goods. Mr. Merchan would lead the company’s CBD portfolio, eventually launching four unique brands in the United States and facilitating the growth of the company’s operating divisions (https://ibn.fm/g5z3H). His performance would influence his appointment as CEO of the company five months later, taking over from Damian Lopez. Before joining Flora, Mr. Merchan held various positions at Macy’s Inc., including Vice President (“VP”) of Workforce Strategy and Operations, VP of Customer Experience and Selling Support Services, and Group VP of National Merchandising and Sales Beauty. Over his 9-year tenure at Macy’s, Mr. Merchan led various sales and marketing initiatives that included the B2B corporate sales team responsible for bringing in $160 million in annual revenue for the company. This earned him the Macy’s Chairman’s award for four consecutive years, from 2015 to 2018 (https://ibn.fm/QgMSx). During the announcement of his appointment as Flora’s head, the outgoing CEO, Damian Lopez, noted the company’s plan to adapt its team to put Flora Growth in the best position possible to carry on its impressive growth trajectory. In addition, he lauded Mr. Merchan’s performance as President of Consumer Goods, citing how impressive of a business executive he was and how integral he would be for the company’s growth going forward. “I am excited to leverage my past consumer packaged goods experience at Macy’s while continuing to work closely with Damian and leveraging his knowledge of the company and the industry to make Flora Growth a global cannabis brand,” noted Mr. Merchan (https://ibn.fm/rr4YP). Merchan has since been appointed Flora’s Chairman of the Board, taking over from Bernie Wilson, terming it as a “Testament to what we have built together thus far.” This came on the heels of Flora’s transition from the development stage to a full-scale international distributor with operations in over 12 countries worldwide; all achieved under Merchan’s leadership. Merchan has also spearheaded several mergers and acquisitions (“M&As”), most notably JustCBD and Vessel Brand, which have since set the company up for rapid growth. Flora has since also secured $34.5 million in financing and signed deals with key retail distributors such as Tropi, a Colombia-based distributor, Walmart, and Macy’s. The company also completed its first import of CBD-containing food and beverage products into the United States from Colombia under its Mambe brand. It has also signed an agreement with luxury clothing and lifestyle brand Tonino Lamborghini to distribute designer CBD beverages through this retailer. Flora maintains its revenue guidance for the 2022 financial year to be between $35 and $45 million, incorporating revenue contributions from its various operating divisions, including Vessel Brand. Mr. Merchan is confident that the company will realize these projections, even as it works towards further market expansion and product diversification as time progresses. Under his leadership, Mr. Merchan is slowly turning Flora into a global leader in the CBD space while also helping it execute its strategy to achieve its short-term and long-term objectives. For more information, visit the company’s website at www.FloraGrowth.com. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• Alberta Research Council estimated Canada’s RNG production potential equivalent to 1,200 billion cubic feet annually, equal to ~1/3 of 2017 natural gas consumption
• EverGen Infrastructure is leading the trend towards RNG, owning/operating 4 projects in western Canada with expansion into Ontario through 50% ownership in a large-scale project
• Flush with cash, EverGen is expanding aggressively, with expectations for core projects to generate a range of $50-$60 million in annual revenue

Canada is stepping up its game in a bid to meet its goal of net zero emissions by 2050, a benchmark that has become the target of many countries worldwide. Currently, over 140 countries have officially set targets or are considering a net zero by 2050 commitment. In June 2021, Canada passed the Canadian Net-Zero Emissions Accountability Act, enshrining its vision into law, promptly following that in July by lowering its mid-term goal to emissions levels of 40-45% of 2005 levels by 2030, versus a prior mark of 30 percent. The regulatory atmosphere and social awareness situation couldn’t be better for companies like EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF), which is aggressively expanding nationwide with its Renewable Natural Gas (“RNG”) infrastructure platform. RNG is just like the name implies. Organic waste from sustainable sources such as farms, landfills, and sewage treatment plants are processed, creating a biogas refined into biomethane as output that is equivalent to conventional natural gas and ready for injection into existing pipelines. The digestate byproduct from the process provides solid and liquid end-products for use in other applications, such as fertilizer. The beauty of RNG is that it is produced from infinite sources, as humans and animals will forever produce waste. Decomposing waste contains large amounts of methane, carbon dioxide and hydrogen sulfide. Separating the methane from the contaminants and refining it to 95+ percent purity (just like traditional natural gas) spares the atmosphere from greenhouses gases being burned off or naturally emitted where they contribute to climate change. It goes without mentioning that RNG creates clean gas without drilling a single hole in the ground, a criticism of natural gas production. In the trend towards reuse and sustainability, RNG will play a substantial role. Natural gas is not only used in in homes and businesses, but also increasingly becoming popular in the transportation industry to cleanly power vehicles. In a 2013 report, the Alberta Research Council estimated Canada’s RNG production potential equivalent to 1,200 billion cubic feet annually. That’s more than one-third of the country’s natural gas consumption in 2017. On the continent level, North American gas utilities are targeting 5-15% renewables by volume compared to less than 1% today. Amassing an impressive portfolio of projects and partners, EverGen is establishing itself as a name brand in the RNG industry. The British Columbia-based company acquires, develops, owns, and operates RNG projects using a platform approach to reliably build sustainable infrastructure to supply the North American gas grid with clean energy from organic waste. In the high-merging business, EverGen’s near-term pipeline has the potential to generate over $30 million in annual adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization). EverGen began building its footprint with projects in its home province before moving east to where it now has operations in B.C., Alberta, and Ontario. The company currently has, owns and operates 4 RNG and/or organic processing facilities: Net Zero Waste Abbottsford (B.C), Fraser Valley Biogas (B.C), Sea to Sky Soils (B.C.), and 67% ownership in GrowTEC (Alberta). EverGen also has a 50% stake in Project Radius, a large, 3-phase RNG project in Ontario. RNG produced at Net Zero Waste Abbottsford, Fraser Valley Biogas, and GrowTEC is bought by FortisBC via long-term (10-20 years) offtake agreements. In September, FortisBC agreed to purchase up to 190,000 gigajoules annually of RNG from Fraser Valley Biogas, meaning they’ll take what is produced currently, as well as securing future production as the project is currently being expanded. At GrowTEC, RNG expansion is now 80 percent complete. To maintain its aggressive growth strategy, EverGen recently signed a term sheet for $31 million Senior Term Loan with its existing lender, a subsidiary of Scotiabank. Ultimately being a nice backstop to the $12.8 million in cash on hand at the end of the third quarter, inclusive of $3.5 million already earmarked for expansion projects. By 2024, it is expected that the core group of projects can be producing 2 million gigajoules annually. At $25-$30 per gigajoule, that translates to $50-$60 million in revenue for EverGen. For more information, visit the company’s website at www.EverGenInfra.com. NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

• BEAT has developed technology that collects data to synthesize a 12-lead 3D vector electrocardiogram (“VECG”)
• The device provides physicians with a 12-lead ECG associated with chest pain compared to a baseline ECG for the patient
• This key data enables physicians to assess whether symptoms may be the result of a heart attack

HeartBeam’s (NASDAQ: BEAT) small, portable, easy-to-use heart-attack detection solution was the focus of a recent Big Biz Show episode; the Big Biz Show features fast-talking, hard-hitting discussions on business and finance. During the interview, Big Biz Show host Bob “Sully” Sullivan chatted with HeartBeam founder and CEO Branislav Vajdic, PhD, about the company’s groundbreaking new device, the HeartBeam AIMIGo(TM) 12-lead 3D vector electrocardiogram recording device that is designed to detect heart attacks anytime, anywhere (https://ibn.fm/9rJre).

“Most people know how a 12-lead machine looks,” Vajdic said during the interview. “It’s on a cart with all these wires running around the body. We have developed a 3D-based vector card technology that enables this device to collect enough data to synthesize a 12-lead VECG and provide that to the physician. Every time a patient feels symptoms, they pull this device out of their wallet, press it against their chest, and declare how they feel on the app, and that goes to our cloud, where processing is happening.

Vajdic indicated that the device, which will be prescribed by healthcare providers, will enable physicians to assess whether symptoms may be the result of a heart attack. Contrary to the widely held view of a patient dropping to the floor with a heart attack, most heart attacks manifest themselves as chest pain, which can be of various intensities. Chest pain, explained Vajdic, can be a sign of an occluded artery.

“That means the heart is deprived of oxygen and the cardiac muscle is dying,” he said. “Yet not many people realize that. An average person waits over three hours before they act on chest pain.” After three hours, the “mortality rate goes up by about 40%, so many lives are lost because of that delay. The sooner you intervene, the more cardiac muscle you save.”

On the flip side, he noted, many people head to the ER at any sign of indigestion. About 82% of those visits end up being unnecessary, costing the system more than $10 billion. The lost lives and wasted dollars are what HeartBeam is hoping to eliminate with its HeartBeam AIMI(TM) technology.

The technology is unlike anything else currently available, stated Vajdic, who also called the device a “breakthrough” and noted that it offers personalized data. “Every heart is different,” he explained. “Our diagnostic engine uses your normal state to compare it to your chest pain or perhaps heart attack.”

Both these patented products —HeartBeam AIMI and HeartBeam AIMIGo — are in development. The company noted that it is also committed to continue advancing the full potential of cutting-edge, 12-lead 3D VECG technology. That commitment is demonstrated by recently issued and allowed patents that appear to have the potential for significant market impacts. HeartBeam AIMI and HeartBeam AIMIGo have not yet been cleared by the US Food and Drug Administration for marketing in the USA or other geographies.

For more information, visit the company’s website at www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

• Jupiter Wellness has announced that the “FDA of India” has approved its topical treatment for psoriasis and vitiligo, with a market launch to follow
• The global vitiligo treatment market was valued at $1.2 billion in 2018 and is expected to grow at a CAGR of 5.8%, resulting in a value of approximately $2 billion by 2026
• JW-500, a topical treatment for female sexual wellness, is currently in development with plans to file for pre-IND and Orphan Drug Designation within the next year

Jupiter Wellness (NASDAQ: JUPW), a diversified company that supports health and wellness by researching and developing over-the-counter (“OTC”) products and intellectual property, recently issued a Letter to Shareholders to provide key corporate updates since the company’s last report on September 15, 2022 (https://ibn.fm/0jcD8). In addition to updates to its clinical trial pipeline, entering the potentially lucrative market of Female Sexual Wellness, and obtaining or adding to its intellectual property portfolio, Jupiter Wellness announced that India’s equivalent of the FDA has approved its topical treatment for psoriasis and vitiligo, with a market launch within the country. The company also provided a quick summary of recent highlights and an overview of products with current dispositions. Of the five products currently in development, Jupiter Wellness is developing JW-500, a topical treatment for female sexual wellness. The company has signed an exclusive license with Rejoy, Inc. to develop prescription products for the treatment of nipple neuropathies and associated sexual problems in women that have been treated for breast cancer. This exclusive license includes issued patents and technology, including all formulations. The company plans to file for a pre-IND meeting with the United States Food and Drug Administration (“FDA”) within the next 12 months and intends to seek Orphan Drug Designation (“ODD”). The chemotherapy-induced peripheral neuropathy treatment market was valued at $1.6 billion in 2020 and is expected to register growth at a CAGR of 5.7%, resulting in a value of approximately $2.4 billion by 2027. The growing prevalence of cancer diagnosis and the increase in cases involving chemotherapy-induced peripheral neuropathy are expected to drive the market during the forecast period. The advancement of technology advances and the rising demand for cost-efficient therapeutics are also expected to play a significant role in the market’s growth over time (https://ibn.fm/3OYf9). The company has three products currently on the market:

• Minoxidil Booster(TM) – a topical treatment designed to improve Minoxidil efficacy
• Photocil(TM) – a topical treatment for psoriasis and vitiligo
• NoStingz(TM) – a topical protection from jellyfish, sea lice, and UVA/UVB rays

The Indian Central Drugs Standard Control Organisation (“CDSCO”), under the Directorate General of Health Services, Ministry of Health & Family Welfare, is the National Regulatory Authority (“NRA”) and it has approved Photocil(TM) (branded as PhotoFirst in India) for sale in India. Marketing meetings for the India product launch were discussed between Eris Oaknet Healthcare Pvt. Ltd. and Cosmofix Technovation Pvt. Ltd. Jupiter Wellness is leveraging the growing market, where approximately five in every thousand individuals suffer from vitiligo, a condition defined by loss of pigmentation in the skin (https://ibn.fm/Y6kk8). The global vitiligo treatment market was valued at $1.2 billion in 2018 and is expected to grow at a CAGR of 5.8%, resulting in a value of approximately $2 billion by 2026. Growth in the market is expected to be facilitated by the increased demand for new and innovative treatment options for managing vitiligo (https://ibn.fm/zr2vu). Jupiter Wellness is producing a product pipeline, backed by clinical research to ensure efficacy, which addresses a range of underserved conditions. The revenue generated and reported by the company in the Letter to Shareholders is achieved through a combination of over-the-counter and consumer product sales, contract research agreements, and licensing royalties. For more information, visit the company’s website at www.JupiterWellness.com. NOTE TO INVESTORS: The latest news and updates relating to JUPW are available in the company’s newsroom at https://ibn.fm/JUPW